Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Ocular Therapeutix (NASDAQ:OCUL) will participate in Clinical Trials at the Summit 2026 in Las Vegas on June 12-13, 2026.

Rhea-AI Summary

Ocular Therapeutix (NASDAQ:OCUL) will participate in Clinical Trials at the Summit 2026 in Las Vegas on June 12-13, 2026. Company leaders and external experts will join fireside chats and panels focused on OTX-TKI and retinal diseases.

Multiple sessions will cover efficacy, safety, and program updates.

Argus Jun 4 session

+5.39% close to close Open Argus

Details

News Market Reaction – OCUL

On Jun 4, the day this news came out, OCUL closed 5.39% above the previous close.

Data tracked by StockTitan Argus for the Jun 4 session.

Market Context

On Jun 4, the day this news came out, the stock closed 5.4% above the previous close. A strong posit...

Analysis

On Jun 4, the day this news came out, the stock closed 5.4% above the previous close. A strong positive reaction aligns with OCUL’s ongoing narrative around AXPAXLI and OTX‑TKI, which already showed statistically significant Phase 3 results (p=0.0006) and cash of $666.7M as of Q1 2026. However, the stock has previously sold off after positive updates, and an effective S‑3ASR shelf from Sep 30, 2025 provides flexibility for future capital raises, which could temper sustained gains if used aggressively.

Key Figures

Share price: $8.35 1-day move: 0.48% 52-week range: $6.2301–$16.44 +5 more

Share price

$8.35

Pre‑news current price for OCUL

1-day move

0.48%

Price change over prior 24 hours

52-week range

$6.2301–$16.44

52-week low and high before this news

SOL-1 p-value

p=0.0006

Phase 3 SOL‑1 superiority results for AXPAXLI in wet AMD

Cash balance

$666.7M

Cash as of March 31, 2026 (Q1 2026 results)

Deep Track ownership

20,850,000 shares (9.53%)

Schedule 13G/A as of March 31, 2026

Short interest

11.57%

Reported short interest as percent of float

Days to cover

8.57

Based on reported short interest and volume

Historical Context

5 past events · Latest: Jun 02

5 events

1. Jun 02

   Investor Day announcement

   24h Move

   -6.9%

   Announced June 17, 2026 Investor Day with pipeline and NDA plan updates.

2. May 15

   Inducement grants

   24h Move

   -3.6%

   Reported inducement equity awards to new HR leadership under stock plan.

3. May 08

   Inducement grants

   24h Move

   -3.8%

   Granted stock options and RSUs to newly hired non‑executive employees.

4. May 05

   Earnings and pipeline

   24h Move

   -0.6%

   Reported Q1 2026, positive SOL‑1 Phase 3 data and strong cash runway.

5. Apr 29

   Clinical trial update

   24h Move

   -1.2%

   Announced first patient enrolled in SOL‑X long‑term extension for AXPAXLI.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, neovascular amd, nonproliferative diabetic retinopathy

3 terms

phase 3 medical

"Presentation Title: SOL-1 Phase 3 Superiority Trial: Efficacy Outcomes with OTX-TKI"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

neovascular amd medical

"Superiority Trial: Efficacy Outcomes with OTX-TKI in Neovascular AMD"

Neovascular AMD is an advanced form of age-related macular degeneration where abnormal, leaky blood vessels grow under the central part of the retina, causing rapid and severe loss of central vision; think of it like a leaking pipe damaging the most important part of a camera sensor. It matters to investors because treatments are often ongoing, high-cost medical therapies whose clinical trial results, regulatory approvals and reimbursement decisions can drive large, sustained revenues or sudden swings in a company’s valuation.

nonproliferative diabetic retinopathy medical

"HELIOS Program Update on OTX-TKI in Nonproliferative Diabetic Retinopathy"

An early stage of diabetic eye disease where small blood vessel damage in the retina causes spotting or swelling but has not yet triggered growth of abnormal new vessels. It matters to investors because it represents a large patient pool and a window where treatments or monitoring can prevent progression to sight‑threatening stages, influencing demand for drugs, devices, clinical trial design and regulatory approvals—think of it as catching a leak before the pipe bursts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Clinical Trials at the Summit (CTS) 2026 Presentation Details:

• Fireside Chat with Wiley Chambers, MD
  Fireside Date/Time: Friday, June 12, 2026, 8:05 – 8:30 PM PT
  Moderators: Jeffrey S. Heier, MD, Chief Scientific Officer; Peter K. Kaiser, MD, Chief Development Officer

• Presentation Title: OTX-TKI: Overview of Science
  Session: Clinical Trials Addressing nAMD, DME, and DR
  Presentation Date/Time: Saturday, June 13, 2026,10:41 – 10:45 AM PT
  Presenter: Peter K. Kaiser, MD, Chief Development Officer

• Presentation Title: SOL-1 Phase 3 Superiority Trial: Efficacy Outcomes with OTX-TKI in Neovascular AMD
  Session: Clinical Trials Addressing nAMD, DME, and DR
  Presentation Date/Time: Saturday, June 13, 2026,10:53 – 10:57 AM PT
  Presenter: Mark R. Barakat, MD

• Presentation Title: Safety and Tolerability Profile of OTX-TKI in Neovascular AMD
  Session: Clinical Trials Addressing nAMD, DME, and DR
  Presentation Date/Time: Saturday, June 13, 2026, 10:57 – 11:01 AM PT
  Presenter: Darius M. Moshfeghi, MD

• Presentation Title: HELIOS Program Update on OTX-TKI in Nonproliferative Diabetic Retinopathy
  Session: Clinical Trials Addressing nAMD, DME, and DR
  Presentation Date/Time: Saturday, June 13, 2026, 11:05 – 11:09 AM PT
  Presenter: Patricio G. Schlottmann, MD

• Fireside Chat: From Global KOL to CEO: The Journey of Innovation, Leadership, and Patient Impact
  Fireside Date/Time: Saturday, June 13, 2026, 11:22 – 11:42 AM PT
  Fireside Moderator: Arshad M. Khanani, MD, MA, FASRS
  Panelist: Pravin U. Dugel, MD, Executive Chairman, President and CEO

• Panel Title: From Innovation to Approval: Bringing Novel Treatments to Market
  Panel Date/Time: Saturday, June 13, 2026, 1:43 – 2:03 PM PT
  Panel Moderator: Pravin U. Dugel, MD, Executive Chairman, President and CEO

Exact presentation times may be subject to change.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Ocular Therapeutix (NASDAQ:OCUL) presenting at Clinical Trials at the Summit 2026?

Ocular Therapeutix is presenting several sessions focused on its investigational therapy OTX-TKI. According to the company, topics include an overview of OTX-TKI science, SOL-1 Phase 3 efficacy outcomes in neovascular AMD, safety and tolerability data, and updates from the HELIOS program in diabetic retinopathy.

When and where will Ocular Therapeutix present at CTS 2026 for OCUL investors?

Ocular Therapeutix will participate at Clinical Trials at the Summit 2026 on June 12-13 in Las Vegas. According to the company, presentations run throughout Saturday, June 13, 2026, with sessions scheduled between 10:41 AM and 2:03 PM Pacific Time, subject to possible time changes.

What is the SOL-1 Phase 3 OTX-TKI trial presentation at CTS 2026 for OCUL?

The SOL-1 Phase 3 presentation will address efficacy outcomes of OTX-TKI in neovascular AMD. According to Ocular Therapeutix, this talk is scheduled for Saturday, June 13, 2026, from 10:53 to 10:57 AM PT in the session on clinical trials for nAMD, DME, and DR.

Which OTX-TKI safety and diabetic retinopathy data will Ocular Therapeutix discuss at CTS 2026?

Ocular Therapeutix plans a presentation on safety and tolerability of OTX-TKI in neovascular AMD and a HELIOS program update in nonproliferative diabetic retinopathy. According to the company, these occur between 10:57 and 11:09 AM PT on Saturday, June 13, 2026.

What leadership and innovation panels will involve Ocular Therapeutix at CTS 2026?

Ocular Therapeutix executives will join a fireside chat on the journey from global KOL to CEO and a panel on bringing novel treatments to market. According to the company, these sessions occur late morning and early afternoon on Saturday, June 13, 2026.

Who from Ocular Therapeutix will moderate or present at CTS 2026 sessions for OCUL?

Key participants include Chief Scientific Officer Jeffrey S. Heier and Chief Development Officer Peter K. Kaiser. According to Ocular Therapeutix, Executive Chairman, President, and CEO Pravin U. Dugel will serve as panel moderator and panelist in separate leadership and innovation sessions.